Photo Credit: National Cancer Institute/Unsplash

Date: 22 June 2020

Institution: University of Virginia

Story published in: Journal of Neuro-Oncology

Digest: A sonodynamic therapy is being tested by researchers at the University of Virginia to treat glioblastomas, one of the deadliest brain cancers. This approach involves making the cancer cells more sensitive by first hitting them with a drug (5-ALA) and then using focused ultrasound to kill them. Both these approaches were individually able to kill cancer cells, but to a lower extent, however, together they are showing promising results


We may be at the tip of the iceberg in terms of intracranial indications for focused ultrasound.

An innovative use of focused ultrasound being pioneered at the School of Medicine, University of Virginia Health System is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.

The technique hits cancer cells with a drug that sensitizes them to sound waves, then blasts them with focused ultrasound. The sound waves create tiny bubbles inside the cancer cells, causing them to die.

The work is early, with researchers testing the concept on cell samples in lab dishes. But their results suggest the technique has “substantial potential for treatment of malignant brain tumors and other challenging oncology indications,” such as lung cancer, breast cancer and melanoma, the researchers report in a new scientific paper. They predict the technique will be particularly useful in treating cancers in sensitive parts of the body that are difficult to access.

“Sonodynamic therapy with focused ultrasound offers a new therapeutic approach to treating patients with malignant brain tumors,” said UVA Health neurosurgeon Jason Sheehan, MD, PhD. “This approach combines two approved options, [the drug] 5-ALA and focused ultrasound, to produce a powerful tumoricidal effect on several different types of glioblastomas.”

Aggressive Glioblastoma

Glioblastomas are the most common malignant brain tumors in adults. They are inevitably fatal, typically within 12 to 18 months of diagnosis. The shortage of effective treatments for this aggressive cancer means new approaches are needed desperately.

To evaluate the potential of their new technique, the UVA researchers looked at its effects on both rat and human cell samples. They examined the benefits of the “sonosensitizing” drug, 5-ALA, and focused ultrasound individually and in combination, and they found that the pairing was far more effective than either alone. The drug reduced the number of viable cancer cells by 5%, while focused ultrasound reduced it by 16%. Together, the reduction was 47%.

“Focused ultrasound has the potential to improve outcomes for patients with complex brain tumors and other neurosurgical pathologies,” Sheehan said. “We may be at the tip of the iceberg in terms of intracranial indications for focused ultrasound.”

Busting Cancer With Bubbles

Many applications of focused ultrasound rely on the technology’s ability to create tiny points of heat inside the body to burn away harmful cells, or to damage cells enough to provoke an immune response. Sheehan’s approach is notable in that it takes another tack, destroying cancer cells without generating heat.

To test out the new technique, the researchers had to develop custom equipment so they could perform the necessary research on the cell samples. They did this from scratch, using a 3D printer and software at the Charlottesville-based Focused Ultrasound Foundation, a longtime supporter of research at UVA and elsewhere.

The researchers say the new platform will advance similar research in the future. Using it, scientists can quickly screen cell types and sonosensitizing drugs like the one used in UVA’s study. It will also be a benefit in pre-clinical and clinical testing in people, they say.

Pioneering Focused Ultrasound

While the sonosensitizing research is in its earliest phases, Sheehan is launching a separate glioblastoma clinical trial in people using a different focused ultrasound approach. That study will evaluate the technology’s potential to open the brain’s protective barrier briefly so that doctors can deliver treatments to the tumor that they normally can’t.

Sheehan’s research is part of a broad effort at UVA to explore the technology’s potential to treat various types of diseases. For example, UVA researchers are examining its ability to treat breast cancer and epilepsy. Pioneering research by UVA neurosurgeon Jeff Elias, MD, already paved the way for the federal Food and Drug Administration to approve the technology to treat essential tremor, a common movement disorder, and tremor caused by Parkinson’s disease. The treatment for those conditions is now available to appropriate patients.


Sheehan and his colleagues have published their initial glioblastoma results in the Journal of Neuro-Oncology. The research team consisted of Kimball Sheehan, Darrah Sheehan, Mohanad Sulaiman, Frederic Padilla, David Moore, Sheehan and Zhiyuan Xu. Padilla and Moore are employed by the Focused Ultrasound Foundation.

The research was recognized as a gold medal winner in basic science by the AANS/CNS Tumor Section.

In addition, Sheehan and colleagues have seen positive results using a different sonosensitizer, fluorescein, in brain tumor preclinical models. The work also was recently published in the Journal of Neuro-Oncology.

Story Source: University of Virginia

Interested in original article: read here